Skip to main content
Top
Published in: Investigational New Drugs 3/2006

01-05-2006 | Phase II Studies

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study

Authors: Emilio Esteban, MD, Joaquin Fra, Yolanda Fernández, Norberto Corral, José M. Vieitez, Isabel Palacio, José L. de Sande, José L. Fernández, Isabel Muñiz, Noemi Villanueva, Enrique Estrada, Beatriz Mareque, Esther Uña, José M. Buesa, Angel J. Lacave, on behalf of the Grupo Oncológico del Norte de España (“GON”)

Published in: Investigational New Drugs | Issue 3/2006

Login to get access
Metadata
Title
Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study
Authors
Emilio Esteban, MD
Joaquin Fra
Yolanda Fernández
Norberto Corral
José M. Vieitez
Isabel Palacio
José L. de Sande
José L. Fernández
Isabel Muñiz
Noemi Villanueva
Enrique Estrada
Beatriz Mareque
Esther Uña
José M. Buesa
Angel J. Lacave
on behalf of the Grupo Oncológico del Norte de España (“GON”)
Publication date
01-05-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-2478-z

Other articles of this Issue 3/2006

Investigational New Drugs 3/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine